Alcon to acquire US commercialization rights to Simbrinza
Alcon has signed an agreement to receive U.S. commercialization rights to Simbrinza from Novartis, according to a press release.
Simbrinza (brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension) is indicated to reduce IOP in patients with primary open-angle glaucoma or ocular hypertension.
“As the global leader in eye care, the addition of a proven fixed-combination glaucoma therapy is a natural adjacency to our existing portfolio,” Sergio Duplan, president, North America at Alcon, said in the release.
Upon closing, expected in the second quarter of 2021, Alcon will pay $355 million to Novartis. Novartis will continue to sell Simbrinza through a transition period and transfer net profits to Alcon. After the transition, Alcon will manufacture and commercialize Simbrinza for the U.S. market, and Novartis will have the rights to the drop outside of the United States.